These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 29534736)

  • 1. Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine.
    Wargowski E; Johnson LE; Eickhoff JC; Delmastro L; Staab MJ; Liu G; McNeel DG
    J Immunother Cancer; 2018 Mar; 6(1):21. PubMed ID: 29534736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate-Resistant Prostate Cancer.
    Heath EI; Thakur A; Chen W; Hwang C; Paller CJ; Cackowski FC; Boerner JL; Heilbrun L; Smith MP; Schalk DL; Schienschang A; Whitaker SA; Polend A; Smith D; Vaishampayan UN; Dickow B; Lum LG
    Cancer Res Commun; 2024 Jul; 4(7):1715-1725. PubMed ID: 38856749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells.
    Johnson LE; Frye TP; Chinnasamy N; Chinnasamy D; McNeel DG
    Cancer Immunol Immunother; 2007 Jun; 56(6):885-95. PubMed ID: 17102977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Pachynski RK; Morishima C; Szmulewitz R; Harshman L; Appleman L; Monk P; Bitting RL; Kucuk O; Millard F; Seigne JD; Fling SP; Maecker HT; Duault C; Ramchurren N; Hess B; D'Amico L; Lacroix A; Kaiser JC; Morre M; Grégoire A; Cheever M; Yu EY; Fong L
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer.
    McNeel DG; Emamekhoo H; Eickhoff JC; Kyriakopoulos CE; Wargowski E; Tonelli TP; Johnson LE; Liu G
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38101860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T.
    Madan RA; Antonarakis ES; Drake CG; Fong L; Yu EY; McNeel DG; Lin DW; Chang NN; Sheikh NA; Gulley JL
    J Natl Cancer Inst; 2020 Jun; 112(6):562-573. PubMed ID: 32145020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
    Cappuccini F; Bryant R; Pollock E; Carter L; Verrill C; Hollidge J; Poulton I; Baker M; Mitton C; Baines A; Meier A; Schmidt G; Harrop R; Protheroe A; MacPherson R; Kennish S; Morgan S; Vigano S; Romero PJ; Evans T; Catto J; Hamdy F; Hill AVS; Redchenko I
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model.
    Simons BW; Cannella F; Rowley DT; Viscidi RP
    Cancer Immunol Immunother; 2020 Apr; 69(4):641-651. PubMed ID: 32016503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy.
    Zahm CD; Johnson LE; McNeel DG
    Cancer Immunol Immunother; 2019 Oct; 68(10):1661-1669. PubMed ID: 31606777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications.
    Gulley JL; Madan RA; Heery CR
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status of immunological therapies for prostate cancer.
    Antonarakis ES; Drake CG
    Curr Opin Urol; 2010 May; 20(3):241-6. PubMed ID: 20179598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic metastatic prostate cancer vaccines: lessons learnt from urologic oncology.
    Lasek W; Zapała Ł
    Cent European J Urol; 2021; 74(3):300-307. PubMed ID: 34729217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
    Laccetti AL; Subudhi SK
    Curr Opin Urol; 2017 Nov; 27(6):566-571. PubMed ID: 28825923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression.
    Noguchi M; Arai G; Matsumoto K; Naito S; Moriya F; Suekane S; Komatsu N; Matsueda S; Sasada T; Yamada A; Kakuma T; Itoh K
    Cancer Immunol Immunother; 2015 Apr; 64(4):493-505. PubMed ID: 25662406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer.
    Noguchi M; Moriya F; Koga N; Matsueda S; Sasada T; Yamada A; Kakuma T; Itoh K
    Cancer Immunol Immunother; 2016 Feb; 65(2):151-60. PubMed ID: 26728480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of Dendritic Cells Isolated from the Blood of Patients with Prostate Cancer by Ex Vivo Fluid Shear Stress Stimulation.
    Dombroski JA; Antunovic M; Schaffer KR; Hurley PJ; King MR
    Curr Protoc; 2023 Dec; 3(12):e933. PubMed ID: 38047658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial.
    Perez SA; Anastasopoulou EA; Tzonis P; Gouttefangeas C; Kalbacher H; Papamichail M; Baxevanis CN
    Cancer Immunol Immunother; 2013 Oct; 62(10):1599-608. PubMed ID: 23934022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current treatment strategies for advanced prostate cancer.
    Komura K; Sweeney CJ; Inamoto T; Ibuki N; Azuma H; Kantoff PW
    Int J Urol; 2018 Mar; 25(3):220-231. PubMed ID: 29266472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current and emerging role of immunotherapy in prostate cancer.
    Madan RA; Gulley JL
    Clin Genitourin Cancer; 2010 Dec; 8(1):10-6. PubMed ID: 21208850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance.
    Saeed MA; Peng B; Kim K; Rawat K; Kuehm LM; Siegel ZR; Borkowski A; Habib N; Van Tine B; Sheikh N; Tuyen V; Thorek DLJ; Fehniger TA; Pachynski RK
    Cancer Immunol Res; 2024 May; 12(5):559-574. PubMed ID: 38407894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.